<!DOCTYPE html>
<html>
  <head>
    <meta charset="utf-8"/>
    <meta property="og:url" content="https://www.channelnewsasia.com/news/world/roche-buys-us-drugmaker-promedior-for-up-to-us-1-4-billion-to-get-lung-drug-12098036"/>
    <meta property="og:site_name" content="CNA"/>
    <meta property="article:published_time" content="2019-11-15T21:17:00+00:00"/>
    <meta property="og:title" content="Roche buys US drugmaker Promedior for up to US$1.4 billion to get lung drug"/>
    <meta property="og:description" content="Swiss drugmaker Roche is paying up to US$1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease ..."/>
  </head>
  <body>
    <article>
      <h1>Roche buys US drugmaker Promedior for up to US$1.4 billion to get lung drug</h1>
      <address>
        <time datetime="2019-11-15T21:17:00+00:00">15 Nov 2019, 21:17</time>
      </address>
      <p>Swiss drugmaker Roche is paying up to US$1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.</p>
      <p>ZURICH: Swiss drugmaker Roche is paying up to US$1.4 billion to buy U.S. biotech company Promedior, whose main drug candidate against the lung disease idiopathic pulmonary fibrosis is set to begin late-stage trials, Promedior said on Friday.</p>
      <p>The deal includes a payment of US$390 million, plus the potential for US$1 billion more if conditions are met. Promedior's lead asset PRM-151 is being studied in IPF where the firm said it helped improve lung function, on top of current therapies.</p>
      <aside>Advertisement</aside>
      <aside>Advertisement</aside>
      <p>Roche already has an IDF medicine, Esbriet, with 2018 sales of just over US$1 billion.</p>
      <p>(Reporting by John Miller; Editing by Michael Shields)</p>
      <footer>Source: Reuters</footer>
    </article>
  </body>
</html>